Psybio Therapeutics Corp
OTC:PSYBF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
P
|
Psybio Therapeutics Corp
XTSX:PSYB
|
809k CAD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
44.6B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.1B CNY |
Loading...
|
|
| DE |
|
BioNTech SE
NASDAQ:BNTX
|
27.5B USD |
Loading...
|
|
| DK |
|
Genmab A/S
CSE:GMAB
|
127.3B DKK |
Loading...
|
|
| US |
|
United Therapeutics Corp
NASDAQ:UTHR
|
20B USD |
Loading...
|
|
| US |
|
Incyte Corp
NASDAQ:INCY
|
19.6B USD |
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
18.7B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Psybio Therapeutics Corp
Glance View
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-02-08. The firm is developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The firm is in the process of developing its portfolio of product candidates for sale in the pharmaceutical industry. The company has developed a technology platform that enables the generation of its formulation for its lead compound psilocybin, biosynthetic psilocybin, and other targeted tryptamines through a biosynthetic process using genetically modified bacteria through collaboration with Miami University-based in Oxford, Ohio. The firm utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.